期刊
CANCER SCIENCE
卷 112, 期 6, 页码 2481-2492出版社
WILEY
DOI: 10.1111/cas.14903
关键词
DP7-C; hepatocellular carcinoma; hydrogel; peptidyl-prolyl cis/trans isomerase
类别
资金
- National Science and Technology Major Project [2018ZX09201018-013, 2018ZX09733001-001-007]
The combination of GalNAc-Pin1 siRNA with DP7-C nanoparticles and hydrogel enhances the stability and inhibitory effects of Pin1 siRNA, showing potential therapeutic efficacy in a liver cancer model.
Hepatocellular carcinoma (HCC) is one of the most lethal cancers in humans. The inhibition of peptidyl-prolyl cis/trans isomerase (Pin1) gene expression may have great potential in the treatment of HCC. N-Acetylgalactosamine (GalNAc) was used to target the liver. Cholesterol-modified antimicrobial peptide DP7 (DP7-C) acts as a carrier, the GalNAc-siRNA/DP7-C complex increases the uptake of GalNAc-siRNA and the escape of endosomes in hepatocytes. In addition, DP7-C nanoparticles and hydrogel-assisted GalNAc-Pin1 siRNA delivery can effectively enhance the stability and prolong the silencing effects of Pin1 siRNA. In an orthotopic liver cancer model, the GalNAc-Pin1 siRNA/DP7-C/hydrogel complex can potentially regulate Pin1 expression in hepatocellular carcinoma cells and effectively inhibit tumor progression. Our study proves that Pin1 siRNA is an efficient method for the treatment of HCC and provides a sustainable and effective drug delivery system for the suppression of liver cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据